Markman, Ben
The Alfred Hospital · Monash Health · Alfred Health · Monash University
4 papers on CoChatORCID 0000-0002-0080-2842
Most cited papers
- Verified
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J. A., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., et al. (2008) · Cancer Research
PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and Cancer
Cited by 787
- Verified
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Fong, L., Hotson, A., Powderly, J. D., Sznol, M., Heist, R. S., Choueiri, T. K., George, S., Hughes, B. G. M., Hellmann, M. D., Shepard, D. R., et al. (2020) · Cancer Discovery
Adenosine and Purinergic SignalingCancer Immunotherapy and Biomarkers
Cited by 352
- Verified
A gut microbial signature for combination immune checkpoint blockade across cancer types
Gunjur, A., Shao, Y., Rozday, T., Klein, O., Mu, A., Haak, B. W., Markman, B., Kee, D., Carlino, M. S., Underhill, C., et al. (2024) · Nature Medicine
Gut microbiota and healthCancer Immunotherapy and Biomarkers
Cited by 165
- Verified
Phase IB Trial of the Anti‐Cancer Stem Cell DLL4‐Binding Agent Demcizumab with Pemetrexed and Carboplatin as First‐Line Treatment of Metastatic Non‐Squamous NSCLC
McKeage, M. J., Kotasek, D., Markman, B., Hidalgo, M., Millward, M. J., Jameson, M. B., Harris, D. L., Stagg, R. J., Kapoun, A. M., Xu, L., et al. (2018) · Targeted Oncology
Lung Cancer Treatments and MutationsLung Cancer Research Studies
Cited by 74
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free